At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 293 enrolled
Drug / intervention
CNTO 1959 (5 mg) +6 moredrug
Likely dose
CNTO 1959 (5 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)
In Brief
A Phase 2 clinical trial evaluating CNTO 1959 (5 mg), CNTO 1959 (15 mg), and 5 other interventions for Psoriasis. Completed, enrolled 293 participants across 40 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesBelgium, Canada, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedDec 2011
Primary CompletionNov 2012
Study CompletionAug 2013
TodayJul 2026
First PostedDec 1, 2011
Enrollment StartNov 10, 2011
Primary CompletionNov 27, 2012
Study CompletionAug 5, 2013
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 14.6 years ago
Interventions
CNTO 1959 (5 mg)drug
Subcutaneous (SC) injections
CNTO 1959 (15 mg)drug
SC injections
CNTO 1959 (50 mg)drug
SC injections
CNTO 1959 (100 mg)drug
SC injections
CNTO 1959 (200 mg)drug
SC injections
Adalimumabdrug
SC injections
Placebodrug
SC injections